AiViva Biopharma, Inc. is a clinical-stage biotechnology company focused on developing innovative pharmaceutical products to address significant unmet medical needs. Founded in 2015 by experienced professionals with extensive backgrounds in drug development and commercialization, AiViva aims to transform treatment paradigms and reduce the treatment burden for patients and healthcare providers. The company has a diverse pipeline of drug candidates targeting various therapeutic areas, including dermatology, ophthalmology, oncology, and urology, with plans to expand into additional fields.

Central to AiViva's development strategy is their proprietary JEL™ Technology, which enhances the therapeutic effects of drugs by allowing for customizable drug-release profiles. This technology optimizes drug exposure in target tissues and facilitates the creation of indication-specific formulations, thereby improving the benefit-risk profiles of their products. By leveraging JEL™ Technology, AiViva seeks to deliver novel pharmacotherapies that not only meet the needs of patients but also streamline treatment processes for healthcare professionals.

United States

AiViva BioPharma, Inc. is a privately owned clinical stage biotech developing novel technologies to address unmet medical needs by transforming existing treatments to create localized, targeted treatment of diseases while limiting systemic exposure.  Our core competency includes development of drugs using our proprietary JEL™ Technology in specialty therapeutic areas of Dermatology, Ophthalmology, Urology, and Oncology.

AiViva Biopharma, Inc.

Company Details